Age-Dependent Memory Benefits From Pharmacologically Enhanced Naps?

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by University of California, San Diego.
Recruitment status was  Recruiting
Information provided by:
University of California, San Diego Identifier:
First received: October 15, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted

The purpose of this study is to investigate whether

  1. pharmacologically enhanced naps will show increases in specific sleep stages
  2. whether these sleep stages will produces specific increases on memory tests
  3. whether older adults will benefit more than young adults from increased SWS or Stage 2 on subsequent declarative and motor memory tests.

Condition Intervention
Older Adults
Drug: Sodium Oxybate
Drug: Zolpidem
Drug: placebo

Study Type: Interventional

Resource links provided by NLM:

Further study details as provided by University of California, San Diego:

Study Start Date: October 2008
Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sodium Oxybate
2.5g Sodium Oxybate administered during nap
Drug: Sodium Oxybate
2.5g Sodium Oxybate administered during nap
Experimental: Zolpidem
5mg Zolpidem administered during nap
Drug: Zolpidem
5mg Zolpidem administered during nap
Placebo Comparator: Placebo Drug: placebo
Placebo administered during nap


Ages Eligible for Study:   60 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • English-speaking individuals, half men and half women, and between the ages of 60 and 75 years will be recruited. No ethnic group will be specifically excluded from study. All participants will be recruited from general San Diego Community. An education requirement of at least 12 years completed will be imposed, as education may affect performance on the cognitive task.

Exclusion Criteria:

  • Not having a regular sleep-wake schedule (defined as not meeting criteria listed above and/or a Horne-Ostberg Morningness-Eveningness Questionnaire score not between 31-69)
  • Having a sleep disorder (reported or detected on the questionnaires)
  • Any personal or immediate family (i.e., first degree relative) history of diagnosed significant psychopathology
  • Personal history of head injury with loss of consciousness greater than 15 minutes or seizures
  • History of substance dependence
  • Current use of any psychotropic medications
  • Any cardiac, respiratory or other medical condition which may affect cerebral metabolism
  • Given the nature of the stimulus and its presentation, anyone with non-correctable vision and audition impairments will also be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00773032

Contact: Jen Kanady, BA 858-642-3192

United States, California
Laboratory for Sleep and Behavioral Neuroscience Recruiting
La Jolla, California, United States, 92093
Contact: Jen Kanady, BA    858-642-3192   
Sponsors and Collaborators
University of California, San Diego
  More Information

No publications provided

Responsible Party: PI: Sara C. Mednick Ph.D. Identifier: NCT00773032     History of Changes
Other Study ID Numbers: 071529_OA
Study First Received: October 15, 2008
Last Updated: October 15, 2008
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Sodium Oxybate
Adjuvants, Anesthesia
Anesthetics, General
Anesthetics, Intravenous
Central Nervous System Agents
Central Nervous System Depressants
GABA Agents
GABA Agonists
GABA-A Receptor Agonists
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 30, 2015